Inherited risk7 min14 August 2026

Germline testing and tumour profiling: two tests that must not be conflated

One test looks for inherited predisposition across the body; the other looks for acquired changes in a particular tumour. They can overlap but answer different questions.

TYPE AND BOUNDARYEditorial evidence review · clinical questions require a professional pathway

ONE-MINUTE SUMMARY

  • A tumour BRCA/TP53/MMR finding may be inherited but does not prove it.
  • A germline result also affects biological relatives.
  • A VUS is not used as a positive predictive or preventive result.
01

The germline

A constitutional variant is generally present in many tissues and can be inherited by children. Blood or saliva are common specimens, but confirmation strategy changes with possible mosaicism, bone-marrow transplant and clonal haematopoiesis.

02

The somatic profile

Alterations arise in a tumour clone and can differ between primary and metastatic sites. Their purpose is to refine biology, prognosis or treatment sensitivity/resistance in a specific clinical situation.

03

Where the tests intersect

A pathogenic tumour finding in BRCA1/2, PALB2, MMR or TP53 can trigger separate germline confirmation. Allele fraction can inform a hypothesis but does not establish origin or replace separate germline testing and counselling.

04

Why paired tumour–normal can help

Paired analysis helps separate acquired from constitutional variants and reduce some misinterpretation, including clonal haematopoiesis. It also needs specific consent, a return-of-results policy and protection of family-relevant data.

05

What changes for a family

A confirmed pathogenic germline variant can change carrier surveillance and enable cascade testing for adult relatives. A relative’s negative result is informative only when the familial pathogenic variant is already known.

EDITORIAL PASSPORT

Publisher
OOO NPO Nauchnye Tekhnologii
Format
Editorial evidence review
Sources checked
Sources
5

Named external review is disclosed only after documented completion. Factual or scientific errors can be reported through the editorial route.

Found an error?

REFERENCES

Sources behind the review.

  1. GeneReviews: hereditary cancer overview
  2. ACMG/AMP germline variant classification
  3. ACMG Secondary Findings v3.3
  4. ASCO somatic genomic testing PCO
  5. ESMO tumour-only germline follow-up
USE BOUNDARY

This review explains evidence and questions for a clinician. It does not interpret an individual DNA file, diagnose or prescribe treatment.